MHRA advice: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes (December 2018) (www.gov.uk).

ELBASVIR/GRAZOPREVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 50mg/100mg (Zepatier®) (s)

GLECAPREVIR/PIBRENTASVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 100mg/40mg (Maviret®)

LEDIPASVIR/SOFOSBUVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 90mg/400mg (Harvoni®) (s)

RIBAVIRIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Capsules 200mg (s)

SOFOSBUVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 400mg (s)

SOFOSBUVIR/VELPATASVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 400mg/100mg (Epclusa®)

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 400mg/100mg/100mg (Vosevi®)

TENOFOVIR DISOPROXIL FUMARATE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 245mg (as fumarate) (s) 

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Editorial Information

Document Id: F287